STOCK TITAN

Burning Rock Biotech Ltd - BNR STOCK NEWS

Welcome to our dedicated news page for Burning Rock Biotech (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Burning Rock Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Burning Rock Biotech's position in the market.

Rhea-AI Summary
Burning Rock Biotech (BNR) reported financial results for Q4 and full year 2023, highlighting revenue declines, new contracts, and operational optimizations. Breakthrough designations for cancer detection tests, positive clinical trial results, and partnerships with pharma companies were key developments. Despite revenue decreases, the company aims for breakeven in H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
-
Rhea-AI Summary
Burning Rock Biotech Limited (BNR) received a notification from NASDAQ regarding its non-compliance with the minimum bid price requirement, giving the company until June 26, 2024, to regain compliance. The company's business operations are not affected by the notification, and it intends to take measures to meet the requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.01%
Tags
none
-
Rhea-AI Summary
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR) announced the passing of all shareholder resolutions at the 2023 annual general meeting, including the ratification of the appointment of Ernst & Young Hua Ming LLP as auditor for the fiscal year ending December 31, 2023, the re-election of three directors, and the authorization of directors to take necessary actions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
Rhea-AI Summary
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR) reported financial results for the three months ended September 30, 2023. The company achieved significant milestones in therapy selection and minimal residual disease, received Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test, and entered into a Master Service Agreement in Oncology Companion Diagnostics with Boehringer Ingelheim. However, the company experienced a 17.5% decrease in revenues compared to the same period in 2022, with a net loss of RMB175.0 million (US$24.0 million) for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.37%
Tags
-
Rhea-AI Summary
Burning Rock Biotech Limited (BNR) will hold its annual general meeting on December 20, 2023, to vote on the appointment of an auditor, re-election of directors, and authorization of necessary actions. Shareholders of record as of November 22, 2023, will be entitled to attend the meeting. The complete audited financial statements and report of auditors for the year ended December 31, 2022, are available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Burning Rock Biotech (BNR) plans to release its unaudited financial results for Q3 2023 on November 30, 2023. The company will host a conference call to discuss the results and provide a live and archived webcast for investors. Please register in advance to participate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
Rhea-AI Summary
Burning Rock Biotech has signed a Master Service Agreement (MSA) with Boehringer Ingelheim in the field of oncology companion diagnostics. The partnership aims to advance clinical trials for Boehringer Ingelheim's MDM2-p53 antagonist, brigimadlin, and develop companion diagnostic products in China. Brigimadlin has received approval for its Phase II clinical trial, offering new treatment options for patients with MDM2-amplified, TP53 wild-type cancers. Burning Rock will provide support for the research and development of brigimadlin and companion diagnostic assays.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.21%
Tags
none
-
Rhea-AI Summary
Burning Rock Biotech announces enrollment of CanCatch® in a 5-year study on MRD in lung cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.94%
Tags
none
-
Rhea-AI Summary
Burning Rock Biotech reports Q2 2023 financial results with revenues of RMB146.3 million, representing an 11.8% increase YoY. Gross profit increased by 21.6% to RMB100.4 million. Total value of new contracts for pharma services increased by 60% YoY to RMB88 million. Net loss decreased to RMB131.2 million from RMB262.1 million in Q2 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
Burning Rock Biotech Ltd

Nasdaq:BNR

BNR Rankings

BNR Stock Data

78.04M
56.48M
0.12%
61.06%
0.39%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
China
Guangzhou

About BNR

Headquartered in China and founded in 2014, Burning Rock, whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology.